What type of study is this?

This is a In Vitro Study study.

December 8, 2025BloodOpen Access

CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

Authors

NZNanfang ZhuoFirst Affiliated Hospital Zhejiang University XLXiangjie LinFirst Affiliated Hospital Zhejiang University PCPengfei ChaiNingbo Center for Disease Control and Prevention

Discussion

Member takes

Implication

Bispecific antibody shows potent anti-leukemic activity in acute myeloid leukemia, suggesting enhanced targeting of leukemia stem cells with favorable safety.

Key Points

The bispecific antibody demonstrated significant T-cell activation, leading to effective cytotoxicity against acute myeloid leukemia cells.
At an E:T ratio of 3:1, the IC50 results highlighted potent antileukemic activity with a focus on IL-2 cytokine release.
Observational analysis using bispecific antibodies against leukemia stem cells showed promising outcomes in both xenograft and patient-derived models.
The findings support the potential for bispecific antibody therapies to provide targeted treatment options in acute myeloid leukemia.

Cite This Study

Zhuo et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236deec https://doi.org/10.1182/blood-2025-2355

View Full Paper

Ask AI

Bookmark

Implication

Bispecific antibody shows potent anti-leukemic activity in acute myeloid leukemia, suggesting enhanced targeting of leukemia stem cells with favorable safety.

CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider